dr. overman on nivolumab and ipilimumab in patients with msi-h crc
Published 8 years ago • 1.5K plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:08
dr. overman discusses nivolumab in patients with dmmr/msi h mcrc
-
1:24
dr. overman on updated findings with nivolumab in metastatic crc
-
1:11
checkmate-8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
2:32
dr. overman discusses updated findings of checkmate-142 in patients with msi-h mcrc
-
1:42
dr. overman on the impact of nivolumab in mcrc
-
2:33
updated results for nivolumab in msi-h colorectal cancer
-
1:26
dr. andre on nivolumab plus ipilimumab in dmmr/msi-h mcrc
-
1:27
dr. overman on ongoing research with immunotherapy in mss crc
-
1:38
dr. overman on remaining questions with immunotherapy in crc
-
0:59
checkmate 8hw: hrqol outcomes of nivolumab and ipilimumab in msi-h/dmmr mcrc
-
1:11
nivolumab/ipilimumab combination data promising in msi-h/dmmr mcrc
-
5:39
nivolumab plus ipilimumab in advanced melanoma
-
1:15
dr. postow on nivolumab combined with ipilimumab in melanoma
-
2:03
promising checkmate-142 data for second-line ipilimumab plus nivolumab in mcrc
-
1:28
dr. overman on distinctions between regorafenib and tas-102 in crc
-
1:05
nivolumab and ipilimumab combination in frontline mcrc
-
2:02
hrqol findings from checkmate 8hw: nivolumab and ipilimumab in msi-h/dmmr mcrc
-
1:27
dr. grothey on fda approval of pembrolizumab in msi-high crc
-
1:15
dr. overman discusses progress with immunotherapy in gi cancer